FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
BPC-157 5mg research peptide vial
Recovery

BPC-157

Body Protection Compound-157

A synthetic gastric peptide widely studied in tissue-repair research.

From $60

In stock · ships in 1–2 business days

  • ✓ 99.78% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
recoverygastrointestinal research

Research Summary

BPC-157 is a synthetic peptide derived from a gastric protein, extensively studied in preclinical research for its role in angiogenesis, cytoprotection, and connective-tissue and gastrointestinal repair models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

BPC-157: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide. It reproduces a partial sequence of a larger protein, called body protection compound, that researchers originally isolated from human gastric juice [1]. Because the fragment remains stable in gastric conditions, much of the literature refers to it as a "stable gastric pentadecapeptide."

It has a large research literature in tissue-repair science. A 2025 systematic review identified 544 articles on BPC-157 published between 1993 and 2024, the large majority of them animal and cell studies [7]. Independent reviewers have noted that most of this work used small rodent models and came from only a handful of research groups [5].

BPC-157 is sometimes confused with TB-500 because the two are often studied side by side in tissue-repair research. They are unrelated molecules: TB-500 is associated with thymosin beta-4 and acts through actin regulation, while BPC-157 is a gastric-protein fragment. See our TB-500 research peptide page for that compound.

BPC-157 molecular identity
SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Length15 amino acids (pentadecapeptide)
Molecular formulaC62H98N16O22
Molecular weight1419.5 g/mol
CAS number137525-51-0
PubChem CID9941957
Other namesBody Protection Compound-157, PL 14736, PL-10, PLD-116 (PubChem synonyms)

Mechanisms studied

Researchers have proposed several overlapping pathways to explain the effects reported in experimental models. None has been confirmed in humans.

Fibroblast migration and the FAK-paxillin pathway

In a 2011 study using tendon explants and cultured tendon fibroblasts from rat Achilles tendon, BPC-157 accelerated explant outgrowth, increased fibroblast survival under hydrogen-peroxide stress, and increased fibroblast migration as concentration rose. It did not directly increase fibroblast proliferation. The authors linked these effects to increased phosphorylation of focal adhesion kinase (FAK) and paxillin [2].

Growth hormone receptor expression

A follow-up study by the same group used cDNA microarray analysis and found growth hormone receptor among the most up-regulated genes in BPC-157-treated rat tendon fibroblasts. Receptor expression rose at both the mRNA and protein level, and adding growth hormone to treated cells increased proliferation and activated JAK2 signaling [3].

Angiogenesis and VEGFR2-Akt-eNOS signaling

In a 2017 study, BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube-formation assays, and accelerated blood-flow recovery in a rat hind-limb ischemia model. In human vascular endothelial cells it increased expression of VEGF receptor 2 (but not VEGF-A), promoted VEGFR2 internalization, and activated the VEGFR2-Akt-eNOS pathway [4].

The nitric oxide system

Reviews from the research group that first described the peptide report interactions between BPC-157 and the nitric oxide system across many rodent models, and propose this as a unifying mechanism for its reported cytoprotective effects [8]. A 2025 narrative review summarized the overall picture as overlapping VEGFR2, Akt-eNOS, and ERK1/2 signaling [6].

Areas of research

Tendon, ligament, and muscle models

Musculoskeletal soft tissue is the most active area of BPC-157 research. A 2019 review of tendon, ligament, and skeletal-muscle studies reported consistently positive healing outcomes in the published models, while noting that most work used small rodent models and that only a handful of research groups had studied the peptide in depth [5]. The 2025 systematic review in orthopaedic sports medicine included 36 studies, 35 of them preclinical, and reported improved functional, structural, and biomechanical outcomes in rodent muscle, tendon, ligament, and bone injury models [7].

Gastrointestinal models

Given its gastric origin, BPC-157 was first studied in gastrointestinal research. Published rodent work covers mucosal injury, models of inflammatory bowel conditions, and fistula models [9] [10]. A 2025 literature and patent review summarizes this preclinical work, including inflammatory bowel disease models, alongside recent patent activity [11].

Wound and vascular models

Reviews have compared BPC-157 with standard angiogenic growth factors such as EGF, FGF, and VEGF across gastrointestinal, tendon, ligament, muscle, and bone healing models [12], and summarized its study in skin-wound models [13].

Open research questions

  • Whether effects seen in rodents replicate in larger animal models and independent laboratories.
  • Pharmacokinetics: preclinical data summarized in the 2025 systematic review describe hepatic metabolism, renal clearance, and a half-life under 30 minutes [7].
  • Long-term effects of sustained pro-angiogenic signaling, since blood-vessel formation also plays a role in pathological processes.

State of the human evidence

Human data on BPC-157 remain very limited. A 2025 narrative review counted three small pilot studies in total, one of them a safety and pharmacokinetics pilot, with no large or controlled trials [6]. The 2025 systematic review found one clinical study in its musculoskeletal scope, a retrospective report on 12 people [7], and found no clinical safety data.

Both reviews concluded that BPC-157 should be regarded as investigational until well-designed clinical trials are completed. Findings from animal and cell models should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. BPC-157 is not approved by the U.S. Food and Drug Administration for any human use [7].
  • Compounding. FDA's list of bulk drug substances that may present significant safety risks (current as of April 22, 2026) shows BPC-157 among substances whose nominations were withdrawn, with the note that compounded drugs containing it may pose a risk of immunogenicity for certain routes of administration [14]. On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend BPC-157 for the 503A bulks list, against the written recommendation of FDA staff. That vote is a non-binding recommendation, and FDA had not acted on it at the time of this review [15].
  • Sport. The World Anti-Doping Agency names BPC-157 under class S0 (non-approved substances), prohibited at all times [16].

Rejuvatide supplies BPC-157 strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of BPC-157 is tested by an independent laboratory for purity by HPLC and identity by mass spectrometry, and is also tested for endotoxin. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

BPC-157 is also a component of our research blends: Glow Blend, Klow Blend, and Wolverine Blend. Browse related compounds in our tissue-repair research category, or read our BPC-157 research overview article.

Storage of lyophilized material

BPC-157 ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of BPC-157.

99.78%HPLC purity
Lot 60730-05Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

BPC-157 FAQ

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) that reproduces part of a protein originally isolated from human gastric juice. It is widely studied in preclinical tissue-repair, angiogenesis, and gastrointestinal research.

Is BPC-157 FDA approved?

No. BPC-157 is not FDA approved for any human use. An FDA advisory committee voted in July 2026 to recommend it for the 503A compounding list, but that recommendation is non-binding and does not make it an approved drug.

Is BPC-157 the same as TB-500?

No. They are different molecules that are often studied together. BPC-157 is a gastric-protein fragment, while TB-500 is associated with thymosin beta-4 and actin regulation.

What sizes of BPC-157 does Rejuvatide offer?

BPC-157 is available in 5mg, 10mg, and 15mg vials of lyophilized powder.

How is Rejuvatide BPC-157 tested?

Each lot is tested by an independent laboratory for HPLC purity, mass-spec identity, and endotoxin. The certificates are published on the product page and in the COA library, matched to the lot number on the vial.

Is BPC-157 for human use?

No. Rejuvatide sells BPC-157 for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

Is BPC-157 banned in sport?

Yes. The World Anti-Doping Agency lists BPC-157 under S0, non-approved substances, which are prohibited at all times.

References

  1. PubChem. BPC 157, Compound CID 9941957. National Library of Medicine. Source
  2. Chang CH, Tsai WC, Lin MS, et al. J Appl Physiol (1985). 2011;110(3):774-80. PubMed 21030672
  3. Chang CH, Tsai WC, Hsu YH, et al. Molecules. 2014;19(11):19066-77. PubMed 25415472
  4. Hsieh MJ, Liu HT, Wang CN, et al. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966
  5. Gwyer D, Wragg NM, Wilson SL. Cell Tissue Res. 2019;377(2):153-159. PubMed 30915550
  6. McGuire FP, Martinez R, Lenz A, et al. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PubMed 40789979
  7. Vasireddi N, Hahamyan H, Salata MJ, et al. HSS J. 2025;21(4):485-495. PubMed 40756949
  8. Sikiric P, Seiwerth S, Skrtic A, et al. Pharmaceuticals (Basel). 2025;18(6). PubMed 40573323
  9. Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2011;17(16):1612-32. PubMed 21548867
  10. Sikiric P, Drmic D, Sever M, et al. Curr Pharm Des. 2020;26(25):2991-3000. PubMed 32329684
  11. Józwiak M, Bauer M, Kamysz W, et al. Pharmaceuticals (Basel). 2025;18(2). PubMed 40005999
  12. Seiwerth S, Rucman R, Turkovic B, et al. Curr Pharm Des. 2018;24(18):1972-1989. PubMed 29998800
  13. Seiwerth S, Milavic M, Vukojevic J, et al. Front Pharmacol. 2021;12:627533. PubMed 34267654
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. Regulatory Affairs Professionals Society. FDA advisory committee backs two controversial peptides (July 2026). Source
  16. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-Approved Substances. Source